Ralf J Ludwig Selected Research

Blister (Bulla)

2/2022	Association between TH2 Cytokine Gene Polymorphisms and Risk of Bullous Pemphigoid.
12/2021	Immunoglobulin M pemphigoid.
12/2021	Granzyme B inhibition reduces disease severity in autoimmune blistering diseases.
1/2021	More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
12/2018	Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease.
1/2018	Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.
2/2017	Clinical features and diagnosis of epidermolysis bullosa acquisita.
2/2017	Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.
1/2017	The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita.
1/2017	Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralf J Ludwig Research Topics

Disease

53	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 10/2022 - 01/2011
35	Bullous Pemphigoid (Pemphigoid) 02/2022 - 12/2010
33	Inflammation (Inflammations) 01/2022 - 04/2002
30	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 04/2010
25	Skin Diseases (Skin Disease) 10/2022 - 11/2002
23	Blister (Bulla) 02/2022 - 08/2011
19	Pemphigus (Pemphigus Vulgaris) 03/2022 - 09/2011
13	Hypersensitivity (Allergy) 07/2017 - 12/2005
8	Neoplasms (Cancer) 01/2022 - 04/2004
8	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 04/2002
8	Thrombocytopenia (Thrombopenia) 07/2017 - 11/2006
5	Vesiculobullous Skin Diseases (Subcorneal Pustular Dermatosis) 04/2015 - 04/2010
4	Disease Progression 02/2017 - 02/2016
4	Contact Dermatitis (Eczema, Contact) 03/2010 - 11/2005
3	Infections 10/2022 - 12/2017
3	Thrombosis (Thrombus) 07/2013 - 04/2007
3	Neoplasm Metastasis (Metastasis) 08/2007 - 04/2004
2	Hepatitis 10/2022 - 01/2021
2	Alopecia Areata 01/2022 - 01/2020
2	Acantholysis 01/2019 - 02/2012
2	Atopic Dermatitis (Atopic Eczema) 01/2018 - 01/2018
2	Hemorrhage 07/2013 - 11/2012
2	Rheumatoid Arthritis 02/2013 - 09/2006
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2011 - 09/2006
2	Wells syndrome 07/2005 - 05/2003
1	Hepatitis B 10/2022
1	Confusion (Bewilderment) 10/2022
1	Epidermolysis Bullosa 01/2022
1	IgA Vasculitis (Purpura, Schoenlein Henoch) 12/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Eosinophilia 01/2021

Drug/Important Bio-Agent (IBA)

74	AutoantibodiesIBA 10/2022 - 06/2010
39	Collagen Type VIIIBA 10/2022 - 01/2011
18	Immunoglobulin G (IgG)IBA 01/2022 - 02/2012
17	AntibodiesIBA 10/2022 - 10/2009
12	Heparin (Liquaemin)FDA LinkGeneric 07/2017 - 04/2004
11	Proteins (Proteins, Gene)FDA Link 12/2021 - 11/2011
10	AutoantigensIBA 01/2022 - 01/2012
9	CytokinesIBA 02/2022 - 02/2013
8	AntigensIBA 12/2021 - 01/2012
7	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 04/2010
7	P-SelectinIBA 08/2010 - 03/2004
6	AnticoagulantsIBA 07/2017 - 04/2004
5	Fondaparinux (Arixtra)FDA Link 11/2015 - 12/2005
4	Intravenous Immunoglobulins (IVIG)FDA Link 10/2022 - 04/2010
4	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 03/2013
4	Therapeutic UsesIBA 01/2022 - 12/2017
4	anti-type VII collagen autoantibodyIBA 01/2022 - 01/2017
4	Peptides (Polypeptides)IBA 12/2021 - 06/2011
4	Immunoglobulin A (IgA)IBA 12/2021 - 08/2014
4	Complement System Proteins (Complement)IBA 12/2021 - 11/2011
4	Immunoglobulin E (IgE)IBA 01/2021 - 11/2015
4	Pharmaceutical PreparationsIBA 12/2020 - 11/2006
4	Antigen-Antibody Complex (Immune Complex)IBA 12/2020 - 08/2014
4	EpitopesIBA 01/2019 - 05/2015
4	Biological ProductsIBA 01/2017 - 09/2005
3	Rituximab (Mabthera)FDA Link 03/2022 - 09/2011
3	Interleukin-10 (Interleukin 10)IBA 02/2022 - 08/2014
3	Interleukin-6 (Interleukin 6)IBA 02/2022 - 02/2013
3	DesmogleinsIBA 01/2021 - 01/2019
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 08/2014
3	Collagen Type XVIIIBA 01/2018 - 08/2011
3	Biomarkers (Surrogate Marker)IBA 12/2017 - 08/2010
3	Nadroparin (Nadroparin Calcium)IBA 07/2017 - 12/2005
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2015 - 01/2013
3	DinitrofluorobenzeneIBA 03/2010 - 08/2006
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2022 - 01/2021
2	KalininIBA 01/2022 - 03/2013
2	Desmoglein 3IBA 12/2021 - 02/2012
2	Immunoglobulin M (IgM)IBA 12/2021 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021 - 04/2010
2	Chimeric Antigen ReceptorsIBA 01/2020 - 01/2017
2	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020 - 01/2017
2	Leukotriene B4IBA 01/2017 - 01/2017
2	IntegrinsIBA 11/2015 - 11/2011
2	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 08/2014 - 06/2011
2	Neutralizing AntibodiesIBA 04/2013 - 11/2005
2	SelectinsIBA 04/2007 - 04/2002
2	Enoxaparin (Lovenox)FDA LinkGeneric 03/2006 - 12/2005
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2022
1	Nucleic AcidsIBA 10/2022
1	N-acetyltalosaminuronic acid (NAT)IBA 10/2022
1	Interleukin-4 (Interleukin 4)IBA 02/2022
1	Interleukin-5 (Interleukin 5)IBA 02/2022
1	Interleukin-13IBA 02/2022
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2022
1	Peptide Hydrolases (Proteases)FDA Link 01/2022
1	CollagenIBA 01/2022
1	Granzymes (Granzyme)IBA 12/2021
1	Serine Proteases (Serine Protease)IBA 12/2021
1	Imiquimod (Aldara)FDA LinkGeneric 01/2021
1	Omalizumab (Xolair)FDA Link 01/2021
1	Sitagliptin Phosphate (Januvia)FDA Link 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Local AnestheticsIBA 01/2021
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2021
1	TGX 221IBA 01/2021
1	VildagliptinIBA 01/2021

Therapy/Procedure

15	Therapeutics 10/2022 - 11/2002
2	Precision Medicine 01/2021 - 01/2020